Phosphatidylinositol 3-Kinase (PI3K) Inhibitors as Cancer Therapeutics

Journal of Hematology and Oncology - United Kingdom
doi 10.1186/1756-8722-6-88
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Phosphatidylinositol 3-Kinase Inhibitors Are a Triple Threat to Ovarian Cancer

Clinical Cancer Research
Cancer ResearchOncology
2005English

Treating Cancer With Phosphatidylinositol-3-Kinase Inhibitors: Increasing Efficacy and Overcoming Resistance

Journal of Lipid Research
BiochemistryEndocrinologyCell Biology
2019English

Heterogeneity of Phosphatidylinositol-3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin Activation in Cancer: Is PI3K Isoform Specificity Important?

Frontiers in Oncology
Cancer ResearchOncology
2018English

Histone Deacetylase Inhibitors as Cancer Therapeutics

Annals of Translational Medicine
Medicine
2016English

Phosphatidylinositol-3-Kinase (PI3K)/Akt Signaling Is Functionally Essential in Myxoid Liposarcoma

Molecular Cancer Therapeutics
Cancer ResearchOncology
2019English

Clinical Development of Phosphatidylinositol 3-Kinase Inhibitors for Non-Hodgkin Lymphoma

Biomarker Research
BiochemistryMolecular MedicineClinical Biochemistry
2013English

Phosphatidylinositol-3-Kinase Pathway

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2012English

The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer

Clinical Cancer Research
Cancer ResearchOncology
2017English

Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy